DNA topoisomerases, type II

Preferred Label : DNA topoisomerases, type II;

MeSH definition : DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex.;

MeSH synonym : dna type 2 topoisomerase; dna topoisomerase ii; type ii dna topoisomerase; topoisomerase ii; dna topoisomerase (atp-hydrolysing);

CISMeF synonym : DNA topoisomerases, type II, eukaryotic; EC 5.99.1.- (DNA topoisomerases, type II, eukaryotic); topoisomerases II, eukaryotic; eukaryotic topoisomerases II; DNA topoisomerases II, eukaryotic; DNA topoisomerases, type II, archaeal; EC 5.99.1.- (DNA topoisomerases, type II, archaeal); topoisomerases II, archaeal; archaeal topoisomerases II; DNA topoisomerases, type II, bacterial; EC 5.99.1.- (DNA topoisomerases, type II, bacterial); topoisomerase II, bacterial; bacterial topoisomerase II; DNA topoisomerase II, bacterial;

DeCS synonym : DNA Topoisomerase II beta; TOP2B Protein; Topoisomerase II beta; TOP2A Protein; DNA Topoisomerase II alpha; Topoisomerase II alpha;

MeSH hyponym : Topoisomerase II beta; beta, Topoisomerase II; TOP2B Protein; Topoisomerase II alpha; alpha, Topoisomerase II; TOP2A Protein;

Registry Number MeSH : EC 5.99.1.3;

MeSH annotation : coordinate with BACTERIAL PROTEINS or ARCHAEAL PROTEINS if pertinent;

Wikipedia link : https://en.wikipedia.org/wiki/Dna topoisomerases, type ii;

Is substance : O;

UNII : EC 5.99.1.3;

Details

Origin ID

D004250;

UMLS CUI

C0012863;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- 3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2 [NCIt concept]
- DNA Topoisomerase 2-Beta [NCIt concept]
- DNA topoisomerase type I (single strand cut, ATP-independent) activity [GO term]
- DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity [GO term]
- Deoxyribonucleic acid topoisomerase (adenosine triphosphate-hydrolysing) (substance) [SNOMED CT concept]
- Deoxyribonucleic acid topoisomerase (substance) [SNOMED CT concept]
- Topoisomerase [NCIt concept]
- Topoisomerase, dna, II, alpha [OMIM gene]
- dna topoisomerase [SNOMED Notion]
- dna topoisomerase (atp-hydrolysing) [SNOMED Notion]
Currated CISMeF NLP mapping
- Topoisomerase II [NCIt concept]
Indexing information
- (eta6-p-cymene)ruthenium(2-anthracen-9-ylmethylene-N-ethylhydrazinecarbothioamide) [MeSH Supplementary Concept]
- 1,2,3-O-acetyl-1,2,3-demethyl-N-(4'-nitrobenzoyl)deacetylthiocolchicine [MeSH Supplementary Concept]
- 1-(3'-hydroxypropyl)-4,6,8-trimethylfuro(2,3-h)quinolin-2(1H)-one [MeSH Supplementary Concept]
- 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxyic acid [MeSH Supplementary Concept]
- 1-cyclopropyl-6-hydroxy-8-methyl-4-oxo-7-(1,2,3,4-tetrahydro-2-isoquinolyl)-1,4-dihydroquinoline-3-carboxylic acid [MeSH Supplementary Concept]
- 12,13-dihydro-N-methyl-6,11,13-trioxo-5H-benzo(4,5)cyclohepta(1,2-b)naphthalen-5,12-imine [MeSH Supplementary Concept]
- 2,3-dihydroindolizino(7,6,5-kl)acridinium chloride [MeSH Supplementary Concept]
- 2,6-bis(2-chloroacetamido)anthraquinone [MeSH Supplementary Concept]
- 2-(2'-(dimethylamino)ethyl)-1,2-dihydro-7-ethoxydibenz(de,h)isoquinoline-1,3-dione [MeSH Supplementary Concept]
- 2-(2-dimethylamino)-6-thia-2-azabenzo(def)chrysene-1,3-dione [MeSH Supplementary Concept]
- 2-(4-methoxyphenyl)-5-((4-methylpiperazin-1-yl)-3H-imidazo(4,5-b)pyridin-2-yl)-3H-imidazo(4,5-b)pyridine [MeSH Supplementary Concept]
- 29-acetoxy-3-methoxyserrat-14-en-21-ol [MeSH Supplementary Concept]
- 3'-deamino-3'-hydroxydoxorubicin [MeSH Supplementary Concept]
- 3-(2-(dimethylamino)ethylamino)-N-(4,9-dioxo-4,9-dihydronaphtho(2,3-b)thiophen-3-yl)propanamide [MeSH Supplementary Concept]
- 3-(diethylamino)-N-(4,9-dioxo-4,9-dihydronaphtho(2,3-b)thiophen-3-yl)propanamide [MeSH Supplementary Concept]
- 3-O-coumaroylbetulinic acid [MeSH Supplementary Concept]
- 3-oxolanost-9(11)-ene-24,25-diol [MeSH Supplementary Concept]
- 4'-O-demethyl-4-(4''-(benzimidazol-2''-yl)anilino)-4-desoxypodophyllotoxin [MeSH Supplementary Concept]
- 4-demethoxy-3'-deamino-3'-hydroxydoxorubicin [MeSH Supplementary Concept]
- 4-demethoxy-3'-deamino-4'-deoxy-4'-aminodaunorubicin [MeSH Supplementary Concept]
- 4-methyl-7-(tetradecanoyl)-2H-1-benzopyran-2-one [MeSH Supplementary Concept]
- 5,8-bis(2-aminoethylamino)-1-azaanthracene-9,10-dione [MeSH Supplementary Concept]
- 6-(arginyl-aminoethyl)-6H-indeno(1,2-c)isoquinolin-5,11-dione [MeSH Supplementary Concept]
- 7-(4-(4-tert-butylbenzyloxy)-1H-indazol-3-ylmethylsulfanyl)-4-methylcoumarin [MeSH Supplementary Concept]
- 8-azabatracylin [MeSH Supplementary Concept]
- 8-desaminobatracylin [MeSH Supplementary Concept]
- 9'-fluoro-10'-(4-methyl-1-piperazinyl)-7'-oxospiro(cyclopropane-1,3'(2'H)-(7H)pyrido(1,2,3-de)(1,4)benzoxazine)-6'-carboxylic acid [MeSH Supplementary Concept]
- 9-bromophenazine-4-carboxamide [MeSH Supplementary Concept]
- A 85226 [MeSH Supplementary Concept]
- BE 10988 [MeSH Supplementary Concept]
- BE 13793C [MeSH Supplementary Concept]
- BE 22179 [MeSH Supplementary Concept]
- BNS 22 [MeSH Supplementary Concept]
- CJ 12371 [MeSH Supplementary Concept]
- CJ 12372 [MeSH Supplementary Concept]
- CJ 12373 [MeSH Supplementary Concept]
- D11 compound [MeSH Supplementary Concept]
- FD 501 [MeSH Supplementary Concept]
- GR 122222X [MeSH Supplementary Concept]
- N,N-bis(3-(5-bromoacridine-4-carboxamido)propyl)methylamine [MeSH Supplementary Concept]
- N,N-bis(3-(5-methylacridine-4-carboxamido)propyl)methylamine [MeSH Supplementary Concept]
- N-(2-(dimethylamino)ethyl)-2-(4-pyridyl)quinoline-8-carboxamide [MeSH Supplementary Concept]
- N-(2-(dimethylamino)ethyl)-5-methyl-4-acridinecarboxamide [MeSH Supplementary Concept]
- NU-ICRF 500 [MeSH Supplementary Concept]
- PD 135042 [MeSH Supplementary Concept]
- PD 138312 [MeSH Supplementary Concept]
- PD 160793 [MeSH Supplementary Concept]
- PD 161148 [MeSH Supplementary Concept]
- SR 103 [MeSH Supplementary Concept]
- SR 107 [MeSH Supplementary Concept]
- SbmC protein, E coli [MeSH Supplementary Concept]
- UCT 1072M1 [MeSH Supplementary Concept]
- UCT 1072M2 [MeSH Supplementary Concept]
- VRT 125853 [MeSH Supplementary Concept]
- WRC 213 [MeSH Supplementary Concept]
- ardisin [MeSH Supplementary Concept]
- azatoxin [MeSH Supplementary Concept]
- bastadin 14 [MeSH Supplementary Concept]
- bis(2,2'-bipyridine)(11-aminopteridine(6,7-f)(1,10)phenanthrolin-13(121H)-one)ruthenium(II) [MeSH Supplementary Concept]
- bis(helenalinyl)glutarate [MeSH Supplementary Concept]
- bis(isoalantodiol-B)glutarate [MeSH Supplementary Concept]
- carbobenzoxycoumarin [MeSH Supplementary Concept]
- chlorobiocic acid [MeSH Supplementary Concept]
- demethylzeylasterone [MeSH Supplementary Concept]
- isoaurostatin [MeSH Supplementary Concept]
- leptosin F [MeSH Supplementary Concept]
- makaluvamine H [MeSH Supplementary Concept]
- makaluvamine I [MeSH Supplementary Concept]
- makaluvamine N [MeSH Supplementary Concept]
- matadine [MeSH Supplementary Concept]
- methyl 3-(4-(bis(2-chloroethyl)amino)phenyl)-2-(2-(4-((N-isopropyl)amidino)phenyl)furan-5-carboxamido)propanoate [MeSH Supplementary Concept]
- morindone [MeSH Supplementary Concept]
- ro 47-3359 [MeSH Supplementary Concept]
- ruthenium ben [MeSH Supplementary Concept]
- ruthenium sal [MeSH Supplementary Concept]
- tridemethyl-N-(4'-nitrobenzoyl)deacetylthiocolchicine [MeSH Supplementary Concept]
Record concept(s)
- DNA topoisomerase II alpha [MeSH concept]
- DNA topoisomerase II beta [MeSH concept]
- DNA topoisomerases, type II [MeSH concept]
Related MeSH Supplementary Concept(s)
- CIN-4 protein, C elegans [MeSH Supplementary Concept]
- DNA topoisomerase VI [MeSH Supplementary Concept]
- MIDGET protein, Arabidopsis [MeSH Supplementary Concept]
- TOP2 protein, S cerevisiae [MeSH Supplementary Concept]
- TOP2 protein, leishmania donovani [MeSH Supplementary Concept]
- TOP2A protein, human [MeSH Supplementary Concept]
- TOP2B protein, human [MeSH Supplementary Concept]
- Top2 protein, Drosophila [MeSH Supplementary Concept]
- Top2a protein, mouse [MeSH Supplementary Concept]
- Top2a protein, rat [MeSH Supplementary Concept]
- Top2b protein, mouse [MeSH Supplementary Concept]
Related MeSH term(s)
- topoisomerase II inhibitors [MeSH Descriptor]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Enzyme [UMLS semantic type]
UMLS correspondences (same concept)
- Deoxyribonucleic acid topoisomerase (adenosine triphosphate-hydrolysing) (substance) [SNOMED CT concept]
- Topoisomerase II [NCIt concept]
- dna topoisomerase (atp-hydrolysing) [SNOMED Notion]
Validated automatic mappings to BTNT
- DNA Topoisomerase 2-Alpha [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients